Physician profile
Taylor V Lam
NPI 1376617787
$11,121.30
in general payments reported to CMS, 2019-2025
23 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,130 · 2020: $434 · 2021: $2,133 · 2022: $2,500 · 2023: $1,274 · 2024: $1,902 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,924.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,854.95 | 2019-2025 | Tryptyr, Eysuvis, Dailies Total1 |
| Sun Pharmaceutical Industries INC. | $1,425.49 | 2020-2025 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $1,318.41 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $1,299.89 | 2022-2025 | Miebo, Xiidra, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $867.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $762.79 | 2020-2023 | |
| Abbvie INC. | $756.88 | 2022-2025 | |
| Allergan, INC. | $530.58 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $513.73 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $346.06 | 2022-2025 | Acuvue |
| Biotissue Holdings INC. | $311.44 | 2022-2023 | |
| Kala Pharmaceuticals, INC. | $261.56 | 2021-2022 | |
| Dompe US, INC. | $208.49 | 2021-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $175.54 | 2019-2022 | |
| Glaukos Corporation | $162.88 | 2021-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $121.75 | 2019 | |
| Harrow Eye, LLC | $73.85 | 2024-2025 | Vevye |
| Shire North American Group INC | $30.45 | 2019 | |
| Sight Sciences, INC. | $26.97 | 2023 | Tearcare System |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Visioneering Technologies, INC. | $18.08 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Thea Pharma INC. | $16.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.